862501-91-5

Usage

Uses

Used in Pharmaceutical Research and Development:
Methyl 4-(((benzyloxy)carbonyl)amino)bicyclo[2.2.2]octane-1-carboxylate is utilized as a key intermediate in the synthesis of novel drugs and medicinally active molecules. Its unique structure allows for the development of compounds with enhanced biological activity and therapeutic potential.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, methyl 4-(((benzyloxy)carbonyl)amino)bicyclo[2.2.2]octane-1-carboxylate is employed as a target for the exploration of its potential biological activity. Its ability to interact with receptors or enzymes in the body is of particular interest, as it may lead to the discovery of new treatments for various diseases and conditions.
Used in Drug Design and Optimization:
Methyl 4-(((benzyloxy)carbonyl)amino)bicyclo[2.2.2]octane-1-carboxylate is used as a structural component in drug design and optimization processes. Its incorporation into new molecular entities can contribute to improved pharmacokinetic and pharmacodynamic profiles, ultimately resulting in more effective and safer medications.

Upstream product

• 100-51-6 benzyl alcohol 
• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 

Downstream Products

• 1245643-16-6 4-(difluoromethyl)bicyclo[2.2.2]octan-1-amine 
• 444344-91-6 4-[[(benzyloxy)carbonyl]amino]-bicyclo[2.2.2]octane-1-carboxylic acid 
• 914619-02-6 4-[2-(4-chloro-phenoxy)-2-methyl-propionylamino]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester 
• 135908-33-7 methyl 4-aminobicyclo[2.2.2]octane-1-carboxylate hydrochloride 

Relevant academic research and scientific papers

2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF

The present application relates to a 2,3-dihydro-1H-pyrrolizine-7-formamide derivative as a nucleoprotein inhibitor and a use in preparation of a drug for treating HBV related diseases. The present application specifically relates to a compound represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with EGFR and/or HER2 activity.

NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF

The present invention relates to inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantane replacements

A series of structurally novel and metabolically stable bridged bicyclic carbocycle and heterocycle adamantane replacements have been synthesized and biologically evaluated. Several of these compounds exhibit excellent human and mouse 11β-HSD1 potency and

BICYCLOESTER DERIVATIVE

SUMMARY Novel bicycloester derivatives and pharmaceutically acceptable salts thereof have high DPP-IV inhibitory activity. SOLVING MEANS The novel bicycloester derivatives are represented by the general formula (1): Pharmaceutically acceptable salts there

BICYCLIC AMIDE DERIVATIVES

Novel bicycloamide derivatives (general formula (1)) and pharmaceutically acceptable salts thereof effectively inhibit DPP-IV. The bicycloamide derivatives are represented by the general formula (1): Pharmaceutically acceptable salts thereof are also included (Example: (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)).

BICYCLO DERIVATIVE

A novel bicyclo derivative represented by the following general formula (1), or a pharmaceutically acceptable salt thereof, acts as an effective DPP-IV inhibitor: One example is (2S,4S)-1-[[N-(4-methylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidi